Loading...

Ovid Therapeutics

DB:1OT
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1OT
DB
$68M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The last earnings update was 45 days ago. More info.


Add to Portfolio Compare Print
  • Ovid Therapeutics has significant price volatility in the past 3 months.
1OT Share Price and Events
7 Day Returns
-2.8%
DB:1OT
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-81.5%
DB:1OT
-10.2%
DE Biotechs
-6%
DE Market
1OT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ovid Therapeutics (1OT) -2.8% -7.8% -49.3% -81.5% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 1OT underperformed the Biotechs industry which returned -10.2% over the past year.
  • 1OT underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Ovid Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Ovid Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Ovid Therapeutics.

DB:1OT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:1OT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:1OT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Ovid Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:1OT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -45.00 Analyst x1 -41.68
2020 -65.00 Analyst x1 -55.75
2021 -81.00 Analyst x1 -64.34
2022 -38.00 Analyst x1 -27.96
2023 19.00 Analyst x1 12.95
2024 22.48 Est @ 18.29% 14.18
2025 25.37 Est @ 12.87% 14.83
2026 27.67 Est @ 9.08% 14.98
2027 29.45 Est @ 6.42% 14.76
2028 30.80 Est @ 4.57% 14.30
Present value of next 10 years cash flows $-103.74
DB:1OT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $30.80 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$398.39
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $398.39 ÷ (1 + 7.98%)10
$184.95
DB:1OT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-103.74 + $184.95
$81.21
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $81.21 / 38.65
$2.1
DB:1OT Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:1OT represents 0.88023x of NasdaqGS:OVID
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88023x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 2.10 x 0.88023
€1.85
Value per share (EUR) From above. €1.85
Current discount Discount to share price of €1.56
= -1 x (€1.56 - €1.85) / €1.85
15.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Ovid Therapeutics is available for.
Intrinsic value
16%
Share price is €1.56 vs Future cash flow value of €1.85
Current Discount Checks
For Ovid Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Ovid Therapeutics's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Ovid Therapeutics's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ovid Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ovid Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1OT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.11
NasdaqGS:OVID Share Price ** NasdaqGS (2019-04-18) in USD $1.77
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ovid Therapeutics.

DB:1OT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:OVID Share Price ÷ EPS (both in USD)

= 1.77 ÷ -2.11

-0.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ovid Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Ovid Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Ovid Therapeutics's expected growth come at a high price?
Raw Data
DB:1OT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.84x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
2.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Ovid Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ovid Therapeutics's assets?
Raw Data
DB:1OT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.57
NasdaqGS:OVID Share Price * NasdaqGS (2019-04-18) in USD $1.77
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:1OT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:OVID Share Price ÷ Book Value per Share (both in USD)

= 1.77 ÷ 1.57

1.12x

* Primary Listing of Ovid Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ovid Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Ovid Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Ovid Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Ovid Therapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
2.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ovid Therapeutics expected to grow at an attractive rate?
  • Ovid Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Ovid Therapeutics's earnings growth is positive but not above the Germany market average.
  • Unable to compare Ovid Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:1OT Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1OT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 2.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1OT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1OT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 195 184 2
2022-12-31 35 -98 3
2021-12-31 0 -106 3
2020-12-31 0 -86 5
2019-12-31 0 -62 6
DB:1OT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -46 -52
2018-09-30 -44 -50
2018-06-30 -43 -46
2018-03-31 -37 -44
2017-12-31 -31 -65
2017-09-30 -28 -61
2017-06-30 -23 -58
2017-03-31 -21 -53
2016-12-31 -18 -22
2016-09-30 -14 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ovid Therapeutics's earnings are expected to grow by 2.4% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Ovid Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1OT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Ovid Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1OT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.87 0.87 0.87 1.00
2022-12-31 -2.95 -0.30 -8.02 4.00
2021-12-31 -3.21 -0.37 -7.19 4.00
2020-12-31 -2.53 -0.46 -5.55 5.00
2019-12-31 -1.83 -1.26 -2.61 6.00
DB:1OT Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.11
2018-09-30 -2.03
2018-06-30 -1.88
2018-03-31 -1.90
2017-12-31 -3.35
2017-09-30 -3.93
2017-06-30 -4.85
2017-03-31 -5.38
2016-12-31 -2.28
2016-09-30 -1.84

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Ovid Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Ovid Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ovid Therapeutics has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Ovid Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ovid Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ovid Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Ovid Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ovid Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Ovid Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ovid Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1OT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -51.98 19.14 33.79
2018-09-30 -50.04 18.97 31.88
2018-06-30 -46.44 17.89 29.20
2018-03-31 -43.75 17.01 27.16
2017-12-31 -64.81 15.04 49.97
2017-09-30 -61.41 14.30 47.25
2017-06-30 -57.83 13.91 44.05
2017-03-31 -52.97 13.34 39.74
2016-12-31 -22.41 12.95 9.59
2016-09-30 -18.15 11.56 2.41
2015-12-31 -13.16 6.58 6.61
2014-12-31 -0.45 0.34 0.11

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ovid Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Ovid Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Ovid Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ovid Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ovid Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Ovid Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ovid Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ovid Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ovid Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ovid Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Ovid Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ovid Therapeutics Company Filings, last reported 3 months ago.

DB:1OT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 38.81 0.00 41.50
2018-09-30 49.97 0.00 52.51
2018-06-30 61.12 0.00 62.59
2018-03-31 72.09 0.00 74.16
2017-12-31 83.44 0.00 87.13
2017-09-30 92.96 0.00 96.04
2017-06-30 100.94 0.00 106.12
2017-03-31 42.34 0.00 44.23
2016-12-31 49.29 0.00 51.94
2016-09-30 55.81 0.00 57.75
2015-12-31 68.07 0.00 69.94
2014-12-31 4.74 0.00 4.85
  • Ovid Therapeutics has no debt.
  • Ovid Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Ovid Therapeutics has less than a year of cash runway based on current free cash flow.
  • Ovid Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 50.6% each year.
X
Financial health checks
We assess Ovid Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ovid Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Ovid Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ovid Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Ovid Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ovid Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ovid Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1OT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1OT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ovid Therapeutics has not reported any payouts.
  • Unable to verify if Ovid Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ovid Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ovid Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Ovid Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Ovid Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ovid Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ovid Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Ovid Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jeremy Levin
COMPENSATION $2,129,674
AGE 65
TENURE AS CEO 4.1 years
CEO Bio

Dr. Jeremy Max Levin, BA Zoology, DPhil, MB BChir, has been the Chief Executive Officer of Ovid Therapeutics Inc. since March 2015 and serves as its Executive Director. From 1996 to 2000, Dr. Levin has more than 25 years of experience in the global pharmaceuticals industry, leading companies and people to develop and commercialize medicines that address compelling medical needs worldwide. He served as Global Head of Strategic Alliances at Novartis Institutes for Biomedical Research, Inc., a division of Novartis AG from 2002 to 2007. He served as the Chief Executive Officer and President of Teva Pharmaceutical Industries Limited from May 9, 2012 to October 30, 2013. He served as the President of ZymoGenetics, Inc. since October 12, 2010. He served as the President of Medarex, Inc. since September 2009. Dr. Levin joined Teva in February 2012. From September 2007 to December 2012, Dr. Levin held several roles at Bristol-Myers Squibb Company. He served as Senior Vice President of Strategy, Alliances and Transactions at Bristol-Myers Squibb Company since 2010. He served as Senior Vice President of External Science Technology & Licensing at Bristol-Myers Squibb Company since September 29, 2007. He served as the Global Head of Business Development and Strategic Alliances at the Novartis Institutes of Biomedical Research, Inc. from 2002 to 2007. He served as the Chief Executive Officer of Predix Pharmaceuticals Holdings Inc. From 1998 to 1999, he served as Managing Director of Perseus Capital LLC and from 1992 to 1998, he served as the President and Chief Executive Officer of Cadus Pharmaceutical Corporation. Prior to 1992, he served as Vice President of IG Laboratories, a wholly owned subsidiary of Genzyme Corporation. He has deep experience in the global pharmaceuticals and biotechnology industry. He has been the Chairman of Ovid Therapeutics Inc. since April 2014. He served as the Chairman of Physiome Sciences Inc. He served as the Chairman of Cadus Pharmaceutical Corporation from 1996 to 1998. He has been an Independent & Non-Executive Director of Biocon Limited since January 22, 2015. He has been a Director of H. Lundbeck A/S since 2017. He serves as a Director of ZappRx, Inc. and BIO, the Biotechnology Innovation Organization in the USA. He has served on the Boards of the Emerging Companies Section of the Biotechnology Industry Organization and on the Board of Vialactia, an agricultural genetics company. He serves as a Director of Biotechnology Institute, The. He served as a Director of Cellmark Forensics, Inc. since May 1998, ZymoGenetics, Inc. since October 12, 2010, Medarex, Inc. since September 2009 and Orchid Cellmark Inc. from May 1998 to August 11, 2003. He served as a Director of Predix Pharmaceuticals Holdings Inc. Previously, he served on the Board of various public and private biopharmaceutical companies. He has also served as a practicing physician at university hospitals in England, South Africa and Switzerland. He is recognized among the 'Top 25 Most Influential People in the Biopharmaceutical Industry'. He is a recipient of Kermode Prize for work on novel hypertension drugs. He received Albert Einstein Award for Leadership in Life Sciences awarded by Mr. Shimon Peres and Officer's Cross of the Order of Merit of the Republic of Hungary. He has practiced Internal Medicine at University Hospitals in England, Switzerland and South Africa. He holds BA in Zoology, Masters of Arts in Cell Biology and a Doctorate (D. Phil) in Molecular Biology/DNA structure/Chromatin Structure from the University of Oxford and Degrees of Bachelor of Medicine, Bachelor of Surgery (MB and B. Chir) from the University of Cambridge.

CEO Compensation
  • Jeremy's compensation has increased whilst company is loss making.
  • Jeremy's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Ovid Therapeutics management team in years:

3.1
Average Tenure
53
Average Age
  • The tenure for the Ovid Therapeutics management team is about average.
Management Team

Jeremy Levin

TITLE
Chairman & CEO
COMPENSATION
$2M
AGE
65
TENURE
4.1 yrs

Matthew During

TITLE
Founder
COMPENSATION
$2M
AGE
61

Lora Pike

TITLE
Senior Director of Investor Relations & Public Relations

Ana Ward

TITLE
Senior VP
AGE
49
TENURE
1.6 yrs

Tom Perone

TITLE
Senior VP
TENURE
0.3 yrs

Suzanne Wakamoto

TITLE
Senior Vice President of Human Resources

Anna Kazanchyan

TITLE
Senior Vice President of Product Development
AGE
49

Amit Rakhit

TITLE
Chief Medical Officer and Head of Research & Development
COMPENSATION
$1M
AGE
48
TENURE
3.1 yrs

Dirk Haasner

TITLE
Senior Vice President of Global Regulatory Affairs
COMPENSATION
$1M
AGE
53
TENURE
3.1 yrs

Claude Nicaise

TITLE
Head of Strategic Orphan Regulatory Affairs
AGE
65
Board of Directors Tenure

Average tenure and age of the Ovid Therapeutics board of directors in years:

3.1
Average Tenure
63
Average Age
  • The tenure for the Ovid Therapeutics board of directors is about average.
Board of Directors

Matthew During

TITLE
Founder
COMPENSATION
$2M
AGE
61

Karen Bernstein

TITLE
Director
COMPENSATION
$139K
AGE
65
TENURE
3.6 yrs

Jeremy Levin

TITLE
Chairman & CEO
COMPENSATION
$2M
AGE
65
TENURE
5 yrs

Doug Williams

TITLE
Director
COMPENSATION
$138K
AGE
60
TENURE
3.3 yrs

Barbara Duncan

TITLE
Director
COMPENSATION
$141K
AGE
53
TENURE
1.8 yrs

Bart Friedman

TITLE
Lead Independent Director
COMPENSATION
$131K
AGE
73

Daniel Geschwind

TITLE
Member of Scientific Advisory Board
TENURE
3 yrs

Jacqueline French

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs

Howard Federoff

TITLE
Member of Scientific Advisory Board

David Eidelberg

TITLE
Member of the Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Ovid Therapeutics insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
01. Mar 19 Sell Tradelink Securities, LLC, Asset Management Arm Company 08. Jan 19 22. Jan 19 -17,821 €3.13 €-1,947
01. Mar 19 Buy Tradelink Securities, LLC, Asset Management Arm Company 24. Dec 18 20. Feb 19 329,426 €2.33 €3,593
01. Mar 19 Sell Shira Capital LLC Company 04. Jan 19 08. Jan 19 -5,519 €2.70 €0
01. Mar 19 Buy Shira Capital LLC Company 20. Feb 19 20. Feb 19 2,000,000 €1.76 €0
01. Mar 19 Buy Karen Bernstein Individual 26. Feb 19 26. Feb 19 10,000 €1.78 €17,781
27. Feb 19 Buy Jeremy Levin Individual 22. Feb 19 22. Feb 19 75,000 €1.76 €132,285
17. Aug 18 Buy Karen Bernstein Individual 14. Aug 18 14. Aug 18 10,000 €5.49 €54,855
17. Aug 18 Buy Douglas Williams Individual 14. Aug 18 14. Aug 18 5,000 €5.71 €28,565
X
Management checks
We assess Ovid Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ovid Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate, which has completed Phase 1b/2a trial for rare epileptic encephalopathies. The company has collaboration agreement with Takeda Pharmaceutical Company Limited; and a license agreement with H. Lundbeck A/S. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.

Details
Name: Ovid Therapeutics Inc.
1OT
Exchange: DB
Founded: 2014
$60,827,298
38,647,892
Website: http://www.ovidrx.com
Address: Ovid Therapeutics Inc.
1460 Broadway,
Suite 15044,
New York,
New York, 10036,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS OVID Common Stock Nasdaq Global Select US USD 05. May 2017
DB 1OT Common Stock Deutsche Boerse AG DE EUR 05. May 2017
Number of employees
Current staff
Staff numbers
55
Ovid Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:58
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/15
Last earnings filing: 2019/03/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.